KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer

被引：0

作者：

Shitara, K. ^{[1
]}

Ozguroglu, M. ^{[2
]}

Bang, Y. J. ^{[3
]}

Di Bartolomeo, M. ^{[4
]}

Mandala, M. ^{[5
]}

Ryu, M. H. ^{[6
]}

Fornaro, L. ^{[7
]}

Olesinski, T. ^{[8
]}

Caglevic, C. ^{[9
]}

Chung, H. ^{[10
]}

Muro, K. ^{[11
]}

Gokkurt, E. ^{[12
]}

Mansoor, W. ^{[13
]}

McDermott, R. ^{[14
]}

Schacham-Shmueli, E. ^{[15
]}

Chen, X. ^{[16
]}

Kang, S. P. ^{[16
]}

Mayo, C. ^{[16
]}

Ohtsu, A. ^{[1
]}

Fuchs, C. ^{[17
]}

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[3] Seoul Natl Univ, Coll Med, Seoul, South Korea

[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[5] Papa Giovanni XXIII Hosp, Bergamo, Italy

[6] Asan Med Ctr, Seoul, South Korea

[7] Azienda Osped Univ Pisana, Pisa, Italy

[8] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[9] Inst Oncol Fdn Arturo Lopez Perez, Santiago, Chile

[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[12] HOPE, Hamburg, Germany

[13] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[14] Adelaide & Meath Hosp, Dublin, Ireland

[15] Sheba Med Ctr, Ramat Gan, Israel

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Yale Canc Ctr, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA - 005

引用

页数：1

共 50 条

[31] Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
Janjigian, Y.
Kawazoe, A.
Weber, P.
Luo, S.
Lonardi, S.
Kolesnik, O.
Barajas, O.
Bai, Y.
Shen, L.
Tang, Y.
Wyrwicz, L.
Shitara, K.
Qin, S.
Van Cutsem, E.
Tabernero, J.
Li, L.
Shih, C.
Bhagia, P.
Chung, H.
ANNALS OF ONCOLOGY, 2021, 32 : S227 - S227
[32] Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study
Necchi, A.
Bellmunt, J.
De Wit, R.
Vaughn, D.
Fradet, Y.
Lee, J. L.
Fong, L.
Vogelzang, N.
Climent, M.
Petrylak, D.
Choueiri, T.
Gerritsen, W.
Gurney, H.
Quinn, D.
Culine, S.
Sternberg, C.
Mai, Y.
Puhlmann, M.
Perini, R.
Bajorin, D.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S2 - S2
[33] Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Shitara, Kohei
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-Hee
Caglevic, Christian
Olesinski, Tomasz
Chung, Hyun Cheol
Muro, Kei
Goekkurt, Eray
McDermott, Raymond S.
Mansoor, Wasat
Wainberg, Zev A.
Shih, Chie-Schin
Kobie, Julie
Nebozhyn, Michael
Cristescu, Razvan
Cao, Z. Alexander
Loboda, Andrey
Ozguroglu, Mustafa
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
[34] KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
Wainberg, Z. A.
Jalal, S.
Muro, K.
Yoon, H. H.
Garrido, M.
Golan, T.
Doi, T.
Catenacci, D. V.
Geva, R.
Ku, G.
Bleeker, J.
Bang, Y-J.
Hara, H.
Chung, H. C.
Savage, M.
Wang, J.
Koshiji, M.
Dalal, R.
Fuchs, C. S.
ANNALS OF ONCOLOGY, 2017, 28
[35] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
Rha, Sun Young
Wyrwicz, Lucjan S.
Weber, Patricio Eduardo Yanez
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernandez, Manuel Gonzalez
Li, Jin
Lowery, Maeve Aine
Cil, Timucin
Cruz, Felipe Melo
Oh, Do-Youn
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies
Wainberg, Zev A.
Fuchs, Charles S.
Tabernero, Josep
Shitara, Kohei
Muro, Kei
Van Cutsem, Eric
Bang, Yung-Jue
Chung, Hyun Cheol
Yamaguchi, Kensei
Varga, Eniko
Chen, Jen-Shi
Hochhauser, Daniel
Thuss-Patience, Peter C.
Al-Batran, Salah-Eddin
Garrido, Marcelo
Kher, Uma
Shih, Chie-Schin
Shah, Sukrut
Bhagia, Pooja
Chao, Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[37] Association between fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a phase III study of fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Qin, S.
Xu, R-H.
Wang, F.
Shen, L.
Guo, W.
Liu, T.
Li, J.
Bai, Y.
Chen, Z.
Wang, J.
Pan, Y.
Shu, Y.
Zhao, F.
Cheng, Y.
Ye, F.
Gu, K.
Zhang, T.
Pan, H.
Liu, Q.
Fan, S.
ANNALS OF ONCOLOGY, 2024, 35 : S897 - S897
[38] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Y-J.
Van Cutsem, E.
Fuchs, C. S.
Ohtsu, A.
Tabernero, J.
Ilson, D. H.
Hyung, W. J.
Strong, V. E.
Goetze, T. O.
Yoshikawa, T.
Tang, L. H.
Hwang, P. M. T.
Adelberg, D.
Shitara, K.
ANNALS OF ONCOLOGY, 2018, 29 : 268 - 268
[39] Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.
Yin, Xianli
Zhang, Yun
Deng, Yanhong
Xu, Nong
Xu, Jianming
Li, Lei
Song, Xiaotong
Lu, Haolan
Gong, John
Liu, Dongfang
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Rha, S. Y.
Wyrwicz, L. S.
Weber, P. E. Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Rivera, F.
Alves, G. V.
Garrido, M.
Shiu, K. -k.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F. J. S. M.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Oh, D-y.
ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320

← 1 2 3 4 5 →